BRPI0512161A - métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêutica - Google Patents
métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêuticaInfo
- Publication number
- BRPI0512161A BRPI0512161A BRPI0512161-2A BRPI0512161A BRPI0512161A BR PI0512161 A BRPI0512161 A BR PI0512161A BR PI0512161 A BRPI0512161 A BR PI0512161A BR PI0512161 A BRPI0512161 A BR PI0512161A
- Authority
- BR
- Brazil
- Prior art keywords
- animal
- brain
- methods
- attacks
- adult
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
MéTODOS PARA TRATAR E PREVENIR UM DISTúRBIO PAROXìSMICO EM UM ANIMAL ADULTO OU JOVEM, PARA AUMENTAR O LIMITE DE ATAQUES NO CéREBRO OU TECIDO NEURAL DE UM ANIMAL, PARA TRATAR E EVITAR DOR EM UM ANIMAL E PARA REDUZIR SURTO EPILéPTICO EM CéLULAS CEREBRAIS, E, COMPOSIçãO FARMACêUTICA A invenção refere-se a métodos para aliviar distúrbios paroxísmicos em um animal, particularmente epilepsia, pela modulação de glicólise em células cerebrais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58043604P | 2004-06-17 | 2004-06-17 | |
PCT/US2005/021845 WO2006002121A2 (en) | 2004-06-17 | 2005-06-17 | Compounds and methods for treating seizure and paroxysmal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0512161A true BRPI0512161A (pt) | 2008-02-12 |
Family
ID=35427194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0512161-2A BRPI0512161A (pt) | 2004-06-17 | 2005-06-17 | métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêutica |
Country Status (11)
Country | Link |
---|---|
US (1) | US7795227B2 (pt) |
EP (1) | EP1885379B1 (pt) |
JP (1) | JP2008502705A (pt) |
KR (1) | KR20070034591A (pt) |
CN (1) | CN1972697A (pt) |
AU (2) | AU2005258021B2 (pt) |
BR (1) | BRPI0512161A (pt) |
CA (1) | CA2571055C (pt) |
ES (1) | ES2590259T3 (pt) |
IL (1) | IL179864A0 (pt) |
WO (1) | WO2006002121A2 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020035071A1 (en) * | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US20090252834A1 (en) * | 2004-05-10 | 2009-10-08 | Michael Griffin Hayek | Compositions comprising glucose anti-metabolites |
KR20070034591A (ko) | 2004-06-17 | 2007-03-28 | 위스콘신 얼럼나이 리서어치 화운데이션 | 발작 및 발작병을 치료하기 위한 화합물 및 방법 |
EP1871881A2 (en) * | 2005-02-14 | 2008-01-02 | Wisconsin Alumni Research Foundation | Metabolic-based methods for modulating gene expression |
US20060217303A1 (en) * | 2005-03-25 | 2006-09-28 | Wisconsin Alumni Research Foundation | Compounds and Methods for Treating Seizure Disorders |
DK1880001T3 (da) | 2005-05-31 | 2011-09-12 | Iams Company | Feline probiotiske lactobacilli |
WO2006130188A1 (en) | 2005-05-31 | 2006-12-07 | The Iams Company | Feline probiotic bifidobacteria |
US20060287253A1 (en) * | 2005-06-17 | 2006-12-21 | Kriegler Steven M | Compounds and methods for treating seizure disorders |
US20080089981A1 (en) * | 2006-10-17 | 2008-04-17 | N.V. Nutricia | Ketogenic diet |
US20100222304A1 (en) | 2006-11-02 | 2010-09-02 | Lillian W Chiang | Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis |
JP5799299B2 (ja) * | 2007-02-01 | 2015-10-21 | ザ・アイムス・カンパニーThe Iams Company | ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法 |
RU2429853C2 (ru) * | 2007-02-01 | 2011-09-27 | Дзе Иамс Компани | Способ уменьшения воспаления и окислительного стресса у млекопитающих |
WO2009140624A2 (en) | 2008-05-16 | 2009-11-19 | Takeda San Diego, Inc. | Glucokinase activators |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US8236768B2 (en) | 2008-10-03 | 2012-08-07 | 3B Pharmaceuticals, Inc. | Topical antiviral formulations |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
AU2011285703B2 (en) * | 2010-08-04 | 2016-03-10 | Wisconsin Alumni Research Foundation | Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury |
JP5888746B2 (ja) * | 2010-08-24 | 2016-03-22 | 国立大学法人 宮崎大学 | マトリックスメタロプロテアーゼ活性抑制組成物 |
US10668041B2 (en) | 2014-12-08 | 2020-06-02 | Societe Des Produits Nestle Sa | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy |
RU2712942C2 (ru) | 2014-12-08 | 2020-02-03 | Сосьете Де Продюи Нестле С.А. | Композиции и способы, включающие триглицериды со средней длиной цепи, для лечения эпилепсии |
CN106668035A (zh) * | 2017-01-24 | 2017-05-17 | 中南大学湘雅三医院 | 一种抗癫痫药物组合物 |
CN115884766A (zh) * | 2020-05-29 | 2023-03-31 | 睿升公司 | 用于使用中链甘油三酯治疗婴儿痉挛的方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08511041A (ja) * | 1993-03-31 | 1996-11-19 | ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルバニア | 哺乳動物生組織の増殖に作用する方法、及びそのための化合物ならびに組成物 |
US5643883A (en) * | 1995-01-19 | 1997-07-01 | Uab Research Foundation | Glucose-6-phosphate uptake inhibitors and novel uses thereof |
US6670330B1 (en) * | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
US6620850B2 (en) * | 2001-09-19 | 2003-09-16 | University Of Florida | Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors |
US7145032B2 (en) * | 2002-02-23 | 2006-12-05 | Washington University | Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto |
RU2005125428A (ru) | 2003-01-10 | 2006-03-10 | Тресхолд Фармасьютикалз, Инк. (Us) | Лечение рака 2-деоксиглюкозой |
KR20050098244A (ko) | 2003-01-10 | 2005-10-11 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 2-데옥시글루코오스를 사용한 암 치료 방법 |
CN1771043A (zh) | 2003-01-10 | 2006-05-10 | 施瑞修德制药公司 | 利用2-脱氧葡萄糖治疗癌症 |
RU2005126042A (ru) | 2003-01-17 | 2006-02-27 | Тресхолд Фармасьютикалз, Инк. (Us) | Лечение доброкачественной гиперплазии простаты |
AU2004206870A1 (en) | 2003-01-17 | 2004-08-05 | Threshold Pharmaceuticals, Inc. | Treatment of benign prostatic hyperplasia using energolytic agents |
US20060172953A1 (en) * | 2003-01-17 | 2006-08-03 | Threshold Pharmaceuticals Inc. | Treatment of benign prostatic hyperplasia using energolytic agents |
KR20070034591A (ko) | 2004-06-17 | 2007-03-28 | 위스콘신 얼럼나이 리서어치 화운데이션 | 발작 및 발작병을 치료하기 위한 화합물 및 방법 |
WO2006024489A2 (en) | 2004-08-30 | 2006-03-09 | Interstitial Therapeutics | Methods and compositions for the treatment of cell proliferation |
GB0419990D0 (en) | 2004-09-09 | 2004-10-13 | Suisse Electronique Microtech | Marking articles |
EP1871881A2 (en) | 2005-02-14 | 2008-01-02 | Wisconsin Alumni Research Foundation | Metabolic-based methods for modulating gene expression |
US20060217303A1 (en) * | 2005-03-25 | 2006-09-28 | Wisconsin Alumni Research Foundation | Compounds and Methods for Treating Seizure Disorders |
US20060287253A1 (en) * | 2005-06-17 | 2006-12-21 | Kriegler Steven M | Compounds and methods for treating seizure disorders |
-
2005
- 2005-06-17 KR KR1020077001201A patent/KR20070034591A/ko not_active Application Discontinuation
- 2005-06-17 CN CNA2005800199480A patent/CN1972697A/zh active Pending
- 2005-06-17 JP JP2007516830A patent/JP2008502705A/ja active Pending
- 2005-06-17 WO PCT/US2005/021845 patent/WO2006002121A2/en active Application Filing
- 2005-06-17 ES ES05787694.8T patent/ES2590259T3/es active Active
- 2005-06-17 US US11/155,200 patent/US7795227B2/en active Active
- 2005-06-17 AU AU2005258021A patent/AU2005258021B2/en active Active
- 2005-06-17 EP EP05787694.8A patent/EP1885379B1/en active Active
- 2005-06-17 BR BRPI0512161-2A patent/BRPI0512161A/pt not_active IP Right Cessation
- 2005-06-17 CA CA2571055A patent/CA2571055C/en active Active
-
2006
- 2006-12-05 IL IL179864A patent/IL179864A0/en unknown
-
2009
- 2009-03-17 AU AU2009201069A patent/AU2009201069A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20070034591A (ko) | 2007-03-28 |
IL179864A0 (en) | 2007-07-04 |
CA2571055C (en) | 2011-11-29 |
EP1885379A2 (en) | 2008-02-13 |
EP1885379B1 (en) | 2016-07-20 |
US20060088517A1 (en) | 2006-04-27 |
AU2005258021A1 (en) | 2006-01-05 |
CA2571055A1 (en) | 2006-01-05 |
AU2009201069A1 (en) | 2009-04-09 |
ES2590259T3 (es) | 2016-11-21 |
WO2006002121A2 (en) | 2006-01-05 |
JP2008502705A (ja) | 2008-01-31 |
WO2006002121A3 (en) | 2006-03-02 |
AU2005258021B2 (en) | 2008-12-18 |
CN1972697A (zh) | 2007-05-30 |
US7795227B2 (en) | 2010-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0512161A (pt) | métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêutica | |
WO2008011083A9 (en) | Compounds for enhancing arginase activity and methods of use thereof | |
WO2006124913A3 (en) | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems | |
CY1111359T1 (el) | Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer | |
IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
WO2004037204A3 (en) | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease | |
WO2008157787A3 (en) | Hydroxylated tolans and related compounds in the treatment of cancer | |
WO2011038210A3 (en) | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity | |
BRPI0417493B8 (pt) | uso de uma toxina botulínica para tratamento de distúrbios da pele | |
EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
WO2007101002A3 (en) | A novel non-selective cation channel in neuronal cells and methods for treating brain swelling | |
DE602006006068D1 (de) | Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd | |
PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
WO2004015130A3 (en) | Modulators of rabggt and methods of use thereof | |
ATE525084T1 (de) | Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus | |
WO2017190044A8 (en) | Methods for detecting and treating pain using brain activity | |
IS8540A (is) | Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma | |
WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
van Luijtelaar | Genetic models of absence epilepsy: new concepts and insights | |
WO2010018996A3 (ko) | 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물 | |
Kalita et al. | Phonophobia and brainstem excitability in migraine | |
EA200702189A1 (ru) | Способ лечения и профилактики диабета второго типа | |
WO2006101910A3 (en) | Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems | |
WO2010036813A8 (en) | Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2140 DE 10/01/2012. |